在长期预防的血管患者中,分析前兆症状和短期预防的需要
Robin Lochbaum1, Thomas K Hoffmann1, Jens Greve1
1Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, Frauensteige 12, Ulm, 89075, Germany.
Orphanet journal of rare diseases
|February 1, 2025
概括
对于长期预防治疗 (LTP) 的遗传性血管炎 (HAE) 患者,可能不需要对所有手术进行短期预防 (STP). 重新考虑牙科手术的强制性STP可以改善急性治疗可用的患者管理.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
- 过敏 过敏是一种过敏.
背景情况:
- 遗传性血管炎 (HAE) 的特点是经常出现,不可预测的胀发作,通常先有前兆症状.
- 目前的HAE管理包括急性治疗,长期预防 (LTP) 和短期预防 (STP) 程序.
- 长期瘤治疗对前兆症状的影响以及在长期瘤治疗患者中需要STP的需要尚不清楚.
研究的目的:
- 调查LTP在治疗遗传性血管 (HAE) 的有效性.
- 评估在接受长期预防 (LTP) 的HAE患者手术中短期预防 (STP) 的必要性.
- 为了评估LTP期间前兆症状的变化.
主要方法:
- 在接受LTP的HAE患者中进行了基于问卷的研究.
- 评估了前兆症状的变化以及具有胀风险的手术 (手术,牙科,内镜) 的发生率.
- 在这些程序中评估了STP的使用和有效性.
主要成果:
- 在接受LTP的26名HAE患者中,18人有0-3次发作;腹部发作是最常见的 (60%).
- 压力和机械刺激是常见的触发因素;感染也被注意到.
- 突破性攻击发生在STP的4/8个手术中;在105个牙科手术中,没有STP的干预后仅发生1次攻击.
结论:
- 在HAE患者的有效LTP牙科手术中,STP的强制性使用需要重新考虑.
- 急性治疗的可用性和没有其他触发因素是关键因素.
- 虽然在LTP期间强度和频率各不相同,但prodromal症状特征保持一致.
相关概念视频
Allergic Reactions
27.2K
Overview
27.2K
Imaging Studies for Cardiovascular System I:Echocardiography
287
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
287
Pharmacovigilance
769
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
233
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
233
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461


